Radiosensitizer

Mechanism of action

Conventional chemotherapeutics are currently being used in conjunction with radiation therapy to increase its effectiveness. Examples include the fluoropyrimidines, gemcitabine and platinum analogs; fluoropyrimidines increase sensitivity by dysregulating S-phase cell cycle checkpoints in tumor cells. Gemcitabine progresses through a similar mechanism, causing cells in the S-phase to disrepair DNA damage caused by the radiation. Platinum analogs such as cisplatin inhibit DNA repair by cross linking strands, and so aggravate the effects of DNA damage induced by radiation. Mechanisms of Action Radiosensitizers enhance the effects of radiation therapy through various mechanisms, broadly classified as:

DNA Damage Enhancement

These agents increase DNA damage caused by radiation or inhibit its repair.

Halogenated pyrimidines: Incorporate into DNA, making it more susceptible to radiation damage. Platinum analogs: Create DNA crosslinks, preventing repair. PARP inhibitors: Block DNA repair enzymes, increasing damage.

Cell Cycle Interference

These agents disrupt the cell cycle, increasing radiosensitivity at specific phases.

Taxanes: Arrest cells in the radiosensitive G2/M phase. Antimetabolites: Interfere with DNA synthesis, leading to cell cycle arrest.

Hypoxia Modification

These agents address low oxygen levels (hypoxia) in tumors, which can hinder radiation effectiveness.

Nitroimidazoles: Mimic oxygen, enhancing free radical formation in hypoxic cells. Oxygen delivery agents: Improve oxygen supply to tumors.

Limitations

One of the major limitations of radiotherapy is that the cells of solid tumors become deficient in oxygen. Solid tumors can outgrow their blood supply, causing a low-oxygen state known as hypoxia. Oxygen is a potent radiosensitizer, increasing the effectiveness of a given dose of radiation by forming DNA-damaging free radicals. Tumor cells in a hypoxic environment may be as much as 2 to 3 times more resistant to radiation damage than those in a normal oxygen environment. Much research has been devoted to overcoming this problem including the use of high pressure oxygen tanks, blood substitutes that carry increased oxygen, hypoxic cell radiosensitizers such as misonidazole and metronidazole, and hypoxic cytotoxins, such as tirapazamine.

Drug development

As of September 2016, there are a number of radiosensitizers in clinical trials.

References

References

1. (January 2003). "The mechanism of action of radiosensitization of conventional chemotherapeutic agents". Seminars in Radiation Oncology.
2. Hall, E.J. and Giaccia, A.J. (2012) Radiobiology for the Radiologist. 7th Edition, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
3. Hall, E.J. and Giaccia, A.J. (2012) Radiobiology for the Radiologist. 7th Edition, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
4. (1994). "Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors". Oncology Research.
5. (2002). "Impact of tumor hypoxia and anemia on radiation therapy outcomes". Oncologist.
6. (8 October 2014). "PharmaEngine, Nanobiotix Enter Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma". businesswire.com.
7. "NanoXray video". Nanobiotix.
8. (2 January 2018). "Nanobiotix to Initiate Trial of NBTXR3 in Head and Neck, Lung Cancers".
9. (5 April 2021). "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall". [[ClinicalTrials.gov]].
10. (5 May 2021). "NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers". [[ClinicalTrials.gov]].
11. (5 May 2021). "NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma". [[ClinicalTrials.gov]].
12. "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx". [[ClinicalTrials.gov]].
13. (9 May 2022). "AF CRT +/- Nimorazole in HNSCC".
14. (November 2011). "Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)". [[ClinicalTrials.gov]].
15. (2016). "Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme". Journal of Neurosurgery.
16. (26 February 2019). "The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (GBM)".